April 27, 2015
SAN DIEGO — Prophylactic indomethacin did not reduce risk for bronchopulmonary dysplasia or death among extremely preterm infants, according to data presented at the Pediatric Academic Societies Annual Meeting.
To investigate associations between prophylactic indomethacin, bronchopulmonary dysplasia and death by 36 weeks gestational age, Erik Jensen, MD, of the Children’s Hospital of Philadelphia, and colleagues assessed infants with a gestational age of 29 weeks or less who were enrolled in the Neonatal Research Network Generic Database between 2008 and 2012. Receipt of supplemental oxygen at 36 weeks gestational age was considered bronchopulmonary dysplasia. The study cohort consisted of 2,671 infants who received prophylactic indomethacin and 5,368 who did not.